novocure(NVCR) - 2025 Q1 - Earnings Call Presentation

© 2025 Novocure GmbH 2 Confidential © 2024 Novocu © 2025 re GmbH Novocure GmbH 1 © 20254 Novocure GmbH GmbH 4 2024 achievements and 2025 milestones ahead | | DRIVING COMMERCIAL | ADVANCING | DELIVERING | | --- | --- | --- | --- | | | ADOPTION | CLINICAL PIPELINE | PRODUCT INNOVATION | | METIS met primary endpoint | 2024 Generated $605 million | | New array FDA approved | | PANOVA-3 met primary endpoint | ACHIEVEMENTS in net revenues | | and rolling-out globally | | LUNAR-2 and KEYNOTE D58 | NSCLC PMA approv ...